893738-74-4

Usage

Uses

Used in Pharmaceutical Synthesis:
Benzenemethanol, 3-cyclopropylis utilized as a key intermediate in the production of antihypertensive drugs, contributing to the development of medications that help regulate blood pressure.
Used in Organic Chemistry:
In the field of organic chemistry, 3-cyclopropylbenzyl alcohol is employed as a valuable building block for the preparation of various biologically active compounds, enhancing the scope of chemical reactions and the creation of novel molecules with potential applications.
Used in Drug Discovery:
Benzenemethanol, 3-cyclopropylalso holds promise in drug discovery, where its unique structure and properties can be leveraged to design and synthesize new pharmaceutical agents with improved therapeutic effects and reduced side effects.

Upstream product

• 148438-02-2 methyl 3-cyclopropylbenzoate 
• 618-89-3 methyl 3-bromobenzoate 

Relevant academic research and scientific papers

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK

The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.